Marked improvement of delayed methotrexate-induced leukoencephalopathy treated with high-dose folinic acid

Research output: Contribution to journalArticle

Abstract

We report the case of a patient with delayed methotrexate (MTX)-induced leukoencephalopathy who showed a marked improvement both in clinical and neuroimaging findings after a high-dose of the active form of folinic acid (leucovorin) treatment. The patient developed progressive affective impairment accompanied by headache, nausea and vomiting after treatment with MTX during the chemotherapy for acute lymphoblastic leukemia, and diagnosed as delayed type MTX-induced leukoencephalopathy. After an intravenous injection of high-dose folinic acid (total 1920 mg), neurological deficits and white matter changes dramatically improved in a few weeks. Although delayed MTX-induced leukoencephalopathy may cause irreversible brain damage, an early treatment with high dose leucovorin may thus facilitate the marked improvement of clinical findings and white matter abnormalities.

Original languageEnglish
Pages (from-to)517-520
Number of pages4
JournalEuropean Journal of Neurology
Volume4
Issue number5
DOIs
Publication statusPublished - 1997

Keywords

  • Acute lymphoblastic leukemia (ALL)
  • High-dose folinic acid
  • Leukoencephalopathy
  • MTX neurotoxicity

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Marked improvement of delayed methotrexate-induced leukoencephalopathy treated with high-dose folinic acid'. Together they form a unique fingerprint.

  • Cite this